Therefore, this study used GEPIA to examine the variation in CD47 expression among carcinoma and normal tissues, TISCH and TIMER databases to explore the connection among CD47 and prostate cancer immunoinfiltrating cells, and in vitro phagocytosis experiments were conducted to block CD47 signals. Here, CD47 is linked to prostate cancer.